Stablepoint Partners LLC Purchases 832 Shares of AstraZeneca PLC (NASDAQ:AZN)

Stablepoint Partners LLC raised its position in AstraZeneca PLC (NASDAQ:AZN) by 4.0% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 21,825 shares of the company’s stock after acquiring an additional 832 shares during the period. Stablepoint Partners LLC’s holdings in AstraZeneca were worth $1,604,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Confluence Investment Management LLC bought a new position in shares of AstraZeneca in the first quarter valued at approximately $27,000. Banque Transatlantique SA bought a new position in shares of AstraZeneca in the fourth quarter valued at approximately $26,000. Mascagni Wealth Management Inc. bought a new position in shares of AstraZeneca in the fourth quarter valued at approximately $29,000. CoreCap Advisors LLC lifted its holdings in shares of AstraZeneca by 31.8% in the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock valued at $42,000 after purchasing an additional 155 shares in the last quarter. Finally, Financial Management Professionals Inc. lifted its holdings in shares of AstraZeneca by 34.4% in the first quarter. Financial Management Professionals Inc. now owns 781 shares of the company’s stock valued at $57,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Trading Down 0.9%

Shares of AZN stock opened at $72.35 on Friday. The stock has a market capitalization of $224.38 billion, a PE ratio of 32.01, a P/E/G ratio of 1.42 and a beta of 0.38. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68. The business has a 50-day moving average of $69.31 and a 200 day moving average of $69.90. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The business had revenue of $13.59 billion during the quarter, compared to analysts’ expectations of $13.71 billion. During the same quarter last year, the business posted $2.06 EPS. The business’s revenue was up 7.2% on a year-over-year basis. As a group, sell-side analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on AZN shares. BNP Paribas started coverage on AstraZeneca in a report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 target price on the stock. UBS Group upgraded AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. Finally, Morgan Stanley started coverage on AstraZeneca in a research note on Wednesday, February 12th. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $85.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.